Table 1 CK18-Asp396 and total CK18 levels in plasma of CRC patients.
From: Circulating cell death products predict clinical outcome of colorectal cancer patients
P1 (n = 49) | P2 (n = 20) | P3 (n = 28) | |
|---|---|---|---|
Mean time to operation (days, range) | -13 (-50-0) | +20 (7–60) | +137 (82–364) |
CK18-Asp396 level (U/l) | |||
Median (IQR) | 59.1 (41.5–88.2) | 74.8 (39.7–107.9) | 55.6 (42.1–79.9) |
P-value | 0.02 vs P1 | 0.11 vs P2 | |
Total CK18 level (U/l) | |||
Median (IQR) | 260.5 (181.6–378.3) | 308.1 (208.7–492.3) | 257.2 (183.8–457.2) |
P-value | 0.08 vs P1 | 0.05 vs P2 |